- Home
- BMEA vs SELF Comparison
BMEA vs SELF Comparison
Compare BMEA & SELF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- SELF
- Stock Information
- Founded
- BMEA 2017
- SELF 1983
- Country
- BMEA United States
- SELF United States
- Employees
- BMEA N/A
- SELF N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- SELF Real Estate Investment Trusts
- Sector
- BMEA Health Care
- SELF Real Estate
- Exchange
- BMEA Nasdaq
- SELF Nasdaq
- Market Cap
- BMEA 65.8M
- SELF 56.9M
- IPO Year
- BMEA 2021
- SELF N/A
- Fundamental
- Price
- BMEA $1.93
- SELF $5.36
- Analyst Decision
- BMEA Strong Buy
- SELF
- Analyst Count
- BMEA 10
- SELF 0
- Target Price
- BMEA $22.30
- SELF N/A
- AVG Volume (30 Days)
- BMEA 2.3M
- SELF 30.8K
- Earning Date
- BMEA 07-30-2025
- SELF 08-08-2025
- Dividend Yield
- BMEA N/A
- SELF 5.44%
- EPS Growth
- BMEA N/A
- SELF 15.74
- EPS
- BMEA N/A
- SELF 0.22
- Revenue
- BMEA N/A
- SELF $12,622,544.00
- Revenue This Year
- BMEA N/A
- SELF N/A
- Revenue Next Year
- BMEA N/A
- SELF N/A
- P/E Ratio
- BMEA N/A
- SELF $24.47
- Revenue Growth
- BMEA N/A
- SELF 3.58
- 52 Week Low
- BMEA $1.29
- SELF $4.70
- 52 Week High
- BMEA $13.07
- SELF $5.89
- Technical
- Relative Strength Index (RSI)
- BMEA 50.04
- SELF 45.02
- Support Level
- BMEA $1.58
- SELF $5.20
- Resistance Level
- BMEA $2.03
- SELF $5.48
- Average True Range (ATR)
- BMEA 0.15
- SELF 0.15
- MACD
- BMEA -0.00
- SELF -0.01
- Stochastic Oscillator
- BMEA 80.00
- SELF 42.71
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to 13 self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.